Invesco Ltd. Acquires 234,337 Shares of Replimune Group, Inc. $REPL

Key Points

• Invesco Ltd. significantly increased its stake in Replimune Group by 266.3%, holding 322,343 shares valued at $3.14 million as of the latest SEC filing.
• Multiple institutional investors have also adjusted their positions, including Boxer Capital and Wellington Management Group, indicating increased institutional interest in Replimune stock.
• Recent analyst ratings for Replimune Group show a negative trend, with price targets significantly reduced by various firms, including a downgrade from Jefferies Financial Group to a target of only $6.00.

Invesco Ltd. increased its stake in Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 266.3% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 322,343 shares of the company's stock after buying an additional 234,337 shares during the period. Invesco Ltd. owned about 0.42% of Replimune Group worth $3,143,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. US Bancorp DE boosted its holdings in Replimune Group by 582.6% in the first quarter. US Bancorp DE now owns 4,594 shares of the company's stock worth $45,000 after purchasing an additional 3,921 shares during the period. Tower Research Capital LLC TRC boosted its holdings in shares of Replimune Group by 696.7% during the fourth quarter. Tower Research Capital LLC TRC now owns 6,772 shares of the company's stock valued at $82,000 after acquiring an additional 5,922 shares during the period. GAMMA Investing LLC grew its position in Replimune Group by 897.2% in the 1st quarter. GAMMA Investing LLC now owns 8,795 shares of the company's stock worth $902,000 after purchasing an additional 7,913 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Replimune Group in the 4th quarter valued at approximately $117,000. Finally, Quantinno Capital Management LP bought a new position in Replimune Group in the 4th quarter valued at about $127,000. Institutional investors own 92.53% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the stock. Cantor Fitzgerald raised shares of Replimune Group from a "neutral" rating to an "overweight" rating in a report on Wednesday, July 30th. Barclays cut Replimune Group from an "overweight" rating to an "equal weight" rating and decreased their target price for the stock from $17.00 to $3.00 in a research report on Wednesday, July 23rd. Wedbush reiterated a "neutral" rating and issued a $4.00 target price (down previously from $19.00) on shares of Replimune Group in a research report on Tuesday, July 22nd. JPMorgan Chase & Co. reaffirmed a "neutral" rating and issued a $9.00 target price (down from $19.00) on shares of Replimune Group in a research report on Tuesday, July 22nd. Finally, BMO Capital Markets lowered shares of Replimune Group from an "outperform" rating to an "underperform" rating and reduced their price objective for the company from $27.00 to $2.00 in a research note on Wednesday, July 23rd. Two research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Replimune Group has a consensus rating of "Hold" and a consensus target price of $6.50.

Insider Buying and Selling

In other Replimune Group news, CFO Emily Luisa Hill sold 9,154 shares of the firm's stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $5.37, for a total value of $49,156.98. Following the completion of the sale, the chief financial officer owned 134,368 shares in the company, valued at approximately $721,556.16. This trade represents a 6.38% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 5.20% of the stock is currently owned by corporate insiders.

Replimune Group Price Performance

Shares of Replimune Group stock traded down $0.05 during midday trading on Wednesday, hitting $5.86. 1,253,188 shares of the company were exchanged, compared to its average volume of 3,973,584. The firm has a 50 day simple moving average of $7.23 and a 200-day simple moving average of $8.88. The company has a debt-to-equity ratio of 0.21, a current ratio of 6.94 and a quick ratio of 6.94. Replimune Group, Inc. has a 52 week low of $2.68 and a 52 week high of $17.00. The firm has a market cap of $457.04 million, a P/E ratio of -1.81 and a beta of 0.51.

Replimune Group (NASDAQ:REPL - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.83) by ($0.12). Research analysts forecast that Replimune Group, Inc. will post -2.97 earnings per share for the current year.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.